This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pension Fund ABP Settles With Merck In Securities Class Action

HEERLEN, Netherlands and AMSTERDAM, Feb. 14, 2013 /PRNewswire/ --  The Dutch pension fund Stichting Pensioenfonds ABP ("ABP"), together with three co-lead plaintiffs, has reached a settlement with Merck and certain of its current and former officers and directors, whereby Merck will pay $215 million to resolve a five-year-old securities class action against all of the Merck defendants. This settlement is part of a $688 million total settlement that Merck agreed to with plaintiffs in two class actions that were combined for trial: Merck & Co., Inc. Vytorin/Zetia Securities Litigation; and Schering-Plough Corporation/Enhance Securities Litigation.

The Merck Vytorin class action, filed in 2008, is pending before Judge Dennis M. Cavanaugh in U.S. District Court for the District of New Jersey.  The settlement comes three weeks before a scheduled trial date of March 4. ABP, International Fund Management SA (part of the Deka Bank Group), the Jacksonville Police and Fire Retirement System, and the General Retirement System of the City of Detroit are the four institutional investor lead plaintiffs in the class action.  The Merck Vytorin class action settlement covers all investors who purchased Merck stock or options between December 6, 2006 and March 28, 2008.

ABP's settlement stems from claims that Merck delayed disclosing for two years results of a clinical trial called ENHANCE - which indicated that Merck's anti-cholesterol drug Vytorin had no statistical advantage in treating atherosclerosis when compared to a generic statin drug, simvastatin. Merck investors alleged that the delay caused a substantial drop in the value of their shares when results of the study were published in 2008.

Merck has denied and continues to deny these claims, contending that the company and its officers acted responsibly in connection with the ENHANCE study. The settlement is subject to approval by Judge Cavanaugh.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,681.82 -48.29 -0.27%
S&P 500 2,070.08 -6.70 -0.32%
NASDAQ 4,994.3720 -14.8420 -0.30%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs